Ledyard National Bank Sells 7,274 Shares of Sanofi (NASDAQ:SNY)

Ledyard National Bank reduced its stake in Sanofi (NASDAQ:SNY) by 23.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,106 shares of the company’s stock after selling 7,274 shares during the period. Ledyard National Bank’s holdings in Sanofi were worth $1,332,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Boston Partners raised its holdings in Sanofi by 0.3% in the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after acquiring an additional 33,657 shares during the period. Bank of New York Mellon Corp lifted its holdings in Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares during the period. Mondrian Investment Partners LTD grew its holdings in Sanofi by 43.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after buying an additional 1,190,141 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its position in Sanofi by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after buying an additional 246,224 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Ratings Changes

SNY has been the topic of several research reports. Argus upped their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $53.66 on Tuesday. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97. The stock has a market capitalization of $136.16 billion, a price-to-earnings ratio of 29.16, a price-to-earnings-growth ratio of 1.57 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company’s 50 day simple moving average is $56.13 and its 200 day simple moving average is $51.62.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. During the same quarter in the previous year, the firm earned $0.95 EPS. Sanofi’s revenue was up 7.8% on a year-over-year basis. As a group, research analysts predict that Sanofi will post 4.25 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.